BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16215885)

  • 1. Mars in decompensated alcoholic liver disease with multi-organ failure.
    Jalan R; Kapoor D; Steiner C; Williams R
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():12. PubMed ID: 16215885
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute alcoholic hepatitis.
    Williams R
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():9-11. PubMed ID: 16215884
    [No Abstract]   [Full Text] [Related]  

  • 3. MARS dialysis in decompensated alcoholic liver disease: a single-center experience.
    Wolff B; Machill K; Schumacher D; Schulzki I
    Liver Transpl; 2007 Aug; 13(8):1189-92. PubMed ID: 17663393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis.
    Sen S; Mookerjee RP; Cheshire LM; Davies NA; Williams R; Jalan R
    J Hepatol; 2005 Jul; 43(1):142-8. PubMed ID: 15878216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First experience in Spain with MARS in three patients with advanced liver failure.
    Aviles J; Macia M; Perez F; Moreno A; Navarro JF; Morales S; Medina ML; Aguiar R; Garcia J
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():20-1. PubMed ID: 16215889
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of split-liver recipients with poor graft function by albumin-dialysis (Mars).
    Loock J; Treichel U; Gerken G; Malago M; Broelsch C; Philipp T; Heemann U
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():18-9. PubMed ID: 16215888
    [No Abstract]   [Full Text] [Related]  

  • 7. Artificial liver support as a bridge to orthotopic liver transplantation in a case of acute liver dysfunction on non-alcoholic steatohepatitis (NASH).
    Gaspari R; Pennisi MA; Mignani V; Gasbarrini A; Mercurio G; Di Campli C; Conti G; Gentiloni Silveri N; Proietti R
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():15-7. PubMed ID: 16215887
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of extracorporeal blood purification methods: Molecular Adsorbent Recirculating System (MARS) for hepatic and renal function replacement].
    Marangoni R
    G Ital Nefrol; 2007; 24 Suppl 38():92-6. PubMed ID: 17922457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extracorporeal support technics in the treatment of multisystem failure. Our experience].
    Berlot G; Barzilay E; Kessler D; Gullo A; Geber D; Ben Zeev I
    Minerva Med; 1989 Dec; 80(12):1309-13. PubMed ID: 2622572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery from multi-organ failure in a patient with a continuous-flow left ventricular assist device.
    Amir O; Delgado RM; Kar B; Gregoric ID; Radovancevic B; Smart F; Cohn W
    J Heart Lung Transplant; 2005 Aug; 24(8):1128-9. PubMed ID: 16102456
    [No Abstract]   [Full Text] [Related]  

  • 11. Critical care organ support: a focus on extracorporeal systems.
    McCunn M; Reed AJ
    Curr Opin Crit Care; 2009 Dec; 15(6):554-9. PubMed ID: 19812488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure.
    Stadlbauer V; Krisper P; Beuers U; Haditsch B; Schneditz D; Jung A; Putz-Bankuti C; Holzer H; Trauner M; Stauber RE
    ASAIO J; 2007; 53(2):187-93. PubMed ID: 17413559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of a phase I trial evaluating an extracorporeal hepatic support device utilizing albumin dialysis.
    Awad SS; Swaniker F; Bartlett RH
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():22-3. PubMed ID: 16215890
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs in liver disease and during albumin dialysis -MARS.
    Majcher-Peszynska J; Peszynski P; Müller SC; Klammt S; Wacke R; Mitzner S; Stange J; Mundkowski R; Hehl EM; Schmidt R; Drewelow B
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():33-5. PubMed ID: 16215894
    [No Abstract]   [Full Text] [Related]  

  • 15. Methods of extracorporeal liver support for treatment of liver cell failure.
    Adham M
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():1-5. PubMed ID: 16215880
    [No Abstract]   [Full Text] [Related]  

  • 16. Increase of octanoate concentrations during extracorporeal albumin dialysis treatments.
    Klammt S; Koball S; Hickstein H; Gloger M; Henschel J; Mitzner S; Stange J; Reisinger EC
    Ther Apher Dial; 2009 Oct; 13(5):437-43. PubMed ID: 19788462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain].
    Avilés J; Macía M; Morales S; Pérez F; Moreno A; Navarro J; Navazo L; García J
    Nefrologia; 2001; 21(4):376-85. PubMed ID: 11816514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients.
    Ronco C
    Clin Nephrol; 1993 Oct; 40(4):187-98. PubMed ID: 8261674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful clinical application of extracorporal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC).
    Huster D; Schubert C; Achenbach H; Caca K; Mössner J; Berr F
    Z Gastroenterol; 2001 Jun; 39 Suppl 2():13-4. PubMed ID: 16215886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.
    Laleman W; Wilmer A; Evenepoel P; Elst IV; Zeegers M; Zaman Z; Verslype C; Fevery J; Nevens F
    Crit Care; 2006; 10(4):R108. PubMed ID: 16859530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.